Correlation Between Acrivon Therapeutics, and Anebulo Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Anebulo Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Anebulo Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and Anebulo Pharmaceuticals, you can compare the effects of market volatilities on Acrivon Therapeutics, and Anebulo Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Anebulo Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Anebulo Pharmaceuticals.

Diversification Opportunities for Acrivon Therapeutics, and Anebulo Pharmaceuticals

-0.19

Correlation Coefficient

Acrivon Therapeutics,  Anebulo Pharmaceuticals

Good diversification

The 3 months correlation between Acrivon and Anebulo is -0.19. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Anebulo Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Anebulo Pharmaceuticals and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Anebulo Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Anebulo Pharmaceuticals has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Anebulo Pharmaceuticals go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and Anebulo Pharmaceuticals

Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to under-perform the Anebulo Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Acrivon Therapeutics, Common is 1.21 times less risky than Anebulo Pharmaceuticals. The stock trades about -0.07 of its potential returns per unit of risk. The Anebulo Pharmaceuticals is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  144.00  in Anebulo Pharmaceuticals on November 29, 2024 and sell it today you would lose (21.00) from holding Anebulo Pharmaceuticals or give up 14.58% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  Anebulo Pharmaceuticals

Acrivon Therapeutics,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in March 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Anebulo Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Anebulo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical and fundamental indicators, Anebulo Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Acrivon Therapeutics, and Anebulo Pharmaceuticals

The main advantage of trading using opposite Acrivon Therapeutics, and Anebulo Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Anebulo Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anebulo Pharmaceuticals will offset losses from the drop in Anebulo Pharmaceuticals' long position.

The idea behind Acrivon Therapeutics, Common and Anebulo Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.